Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.
The corporate update will likely address the progress of Simufilam, Cassava's investigational oral small molecule drug candidate currently being evaluated in two Phase 3 clinical trials for the potential treatment of Alzheimer's disease. Simufilam is designed to target the filamin A protein.
Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.
Alzheimer's disease is a progressive neurodegenerative disorder affecting millions worldwide. The Alzheimer's Association estimates that 6.7 million Americans aged 65 and older are living with Alzheimer's in 2023. The need for effective treatments is significant, as current therapies primarily address symptoms rather than the underlying disease pathology.
Simufilam represents a novel approach to potentially treating Alzheimer's by targeting filamin A, a scaffolding protein that may play a role in the disease. The ongoing Phase 3 trials are designed to evaluate the efficacy and safety of Simufilam in slowing cognitive decline in patients with Alzheimer's disease. The outcomes of these trials are eagerly anticipated by the Alzheimer's research community and patients alike.
A replay of the audio webcast will be available on the Company Presentations page of the Cassava Sciences website for 90 days following the webcast.
